Pembrolizumab,Axitinib,Sunitinib
Merck,Pfizer
['keynote426', 'key,note,42', 'rcc,(-irccs),(-srcc),(-urcc)', 'key,note,426']
now presenting an update on #keynote426 with the longest follow-up to date of an io-tki trial in clear cell rcc. #asco23 continues to be associated with great outcomes. as we continue to accumulate longer follow-up that looks good with io-tki, what is the role 
PGY-2 @BrighamMedRes | @USJLiban MSc '16 MD '18 | @DanaFarber Research '21 | @ASCO #IMG CoP & #JCOCCI Editorial Board | Cancer Genomics |
FCOI: https://t.co/dYsEwGGqP1